BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/23/2022 9:54:46 AM | Browse: 742 | Download: 1672
Publication Name World Journal of Clinical Oncology
Manuscript ID 76757
Country China
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Field of Vision
Article Title Potential of mRNA vaccines to become versatile cancer vaccines
Manuscript Source Invited Manuscript
All Author List Shiu-Ying Tsao
ORCID
Author(s) ORCID Number
Shiu-Ying Tsao http://orcid.org/0000-0002-5787-9664
Funding Agency and Grant Number
Corresponding Author Shiu-Ying Tsao, MBBS, Academic Research, Department of Oncology, Hong Kong SAR Oncology Centre, 12/F McDonald's Building, 46-54 Yee Wo Street, Hong Kong SAR 999077, China. sy_tsao@yahoo.com
Key Words Cancer vaccine; Cyclophosphamide; Metformin; Metronomic chemotherapy; mRNA vaccine; Myocarditis; Tumor microenvironment
Core Tip Although vaccines are effective for pathogen prevention and cancers, hitherto, oncology vaccines have not yet made a very significant clinical impact. Currently, as mRNA vaccines already have a proven safety profile, it is highly appropriate to further develop the decades-old mRNA technology for oncology. Compared to other approved cancer vaccines, oncology mRNA vaccines may be more versatile, pragmatic, affordable and effective. To combat the notoriously resistant tumor microenvironment, the probable mutual enhancement effects with, e.g., metronomic chemotherapy should be fully explored, especially as no significant added toxicity is anticipated. Clearly, undertaking much more research work (especially clinical) is mandatory.
Publish Date 2022-08-23 09:54
Citation Tsao SY. Potential of mRNA vaccines to become versatile cancer vaccines. World J Clin Oncol 2022; 28(32): 4475-4492
URL https://www.wjgnet.com/2218-4333/full/v13/i8/663.htm
DOI https://dx.doi.org/10.5306/wjco.v13.i8.663
Full Article (PDF) WJCO-13-663.pdf
Full Article (Word) WJCO-13-663.docx